Back to all studies
RecruitingNCT06947941

Safety and Efficacy of KarXT + KarX-EC for Alzheimer Disease; Psychosis

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in Canada, ... Confirm recruitment at each site. It is testing Safety and Efficacy of KarXT + KarX-EC for Alzheimer Disease; Psychosis.

Schizophrenia, Alzheimer DiseaseDrugFrom 55 Years to 90 Years
In plain English

Key information made simple

What is this study testing?

This study is testing whether KarXT may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive KarXT, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Australia, in Canada, and in Japan.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: March 25, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
325
Sponsor
Bristol-Myers Squibb
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Australia, Canada, ...
Age range
From 55 Years to 90 Years
Official registry ID
NCT06947941
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer's Disease

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Australia · 2 sites
  • Local Institution - 0020
    Macquarie Park, New South Wales
    Site status: Not Yet Recruiting
  • Local Institution - 0052
    Nedlands, Western Australia
    Site status: Not Yet Recruiting
Canada · 3 sites
  • Local Institution - 0054
    Toronto, Ontario
    Site status: Not Yet Recruiting
  • Local Institution - 0027
    Whitby, Ontario
    Site status: Not Yet Recruiting
  • Local Institution - 0025
    Montreal, Quebec
    Site status: Not Yet Recruiting
Japan · 3 sites
  • Local Institution - 0040
    Suita, Osaka
    Site status: Not Yet Recruiting
  • Local Institution - 0035
    Nankoku-shi
    Site status: Not Yet Recruiting
  • Local Institution - 0034
    Osaka
    Site status: Not Yet Recruiting
United Kingdom · 8 sites
  • Local Institution - 0005
    Exeter, Devon
    Site status: Not Yet Recruiting
  • Local Institution - 0023
    London, England
    Site status: Not Yet Recruiting
  • Local Institution - 0015
    Oxford, Oxfordshire
    Site status: Withdrawn
  • Local Institution - 0009
    Chertsey, Surrey
    Site status: Not Yet Recruiting
  • Local Institution - 0017
    Sheffield, Yorkshire and the Humber
    Site status: Not Yet Recruiting
  • Local Institution - 0018
    Crowborough
    Site status: Withdrawn
  • Local Institution - 0024
    London
    Site status: Not Yet Recruiting
  • Local Institution - 0004
    Motherwell
    Site status: Not Yet Recruiting
United States · 6 sites
  • Gilbert Neurology Partners/CCT Research
    Gilbert, Arizona
    Site status: Recruiting
  • Inland Psychiatric Medical Group.
    Chino, California
    Site status: Recruiting
  • Local Institution - 0001
    Naples, Florida
    Site status: Withdrawn
  • Local Institution - 1401
    Naples, Florida
    Site status: Not Yet Recruiting
  • Local Institution - 0029
    Cleveland, Ohio
    Site status: Not Yet Recruiting
  • Insight Clinical Trials LLC - Independence
    Independence, Ohio
    Site status: Recruiting

Want help reviewing this study?

Loading the security check...
Study ID: NCT06947941. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 55 Years to 90 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Bristol-Myers Squibb, which appears to be a pharmaceutical company. Sponsor website: https://www.bms.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me